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Abstract Critically ill patients are occasionally associ-
ated with an abrupt decline in renal function secondary to
their primary diagnosis. The effect and impact of hae-
modialysis (HD) on insulin kinetics and endogenous
insulin secretion in critically ill patients remains unclear.
This study investigates the insulin kinetics of patients with
severe acute kidney injury (AKI) who required HD treat-
ment and glycaemic control (GC). Evidence shows that
tight GC benefits the onset and progression of renal
involvement in precocious phases of diabetic nephropathy
for type 2 diabetes. The main objective of GC is to reduce
hyperglycaemia while determining insulin sensitivity.
Insulin sensitivity (SI) is defined as the body response to the
effects of insulin by lowering blood glucose levels. Par-
ticularly, this study used SI to track changes in insulin
levels during HD therapy. Model-based insulin sensitivity
profiles were identified for 51 critically ill patients with
severe AKI on specialized relative insulin nutrition titration
GC during intervals on HD (OFF/ON) and after HD (ON/
OFF). The metabolic effects of HD were observed through
changes in SI over the ON/OFF and OFF/ON transitions.
Changes in model-based SI at the OFF/ON and ON/OFF
transitions indicate changes in endogenous insulin secre-
tion and/or changes in effective insulin clearance. Patients
exhibited a median reduction of -29 % (interquartile range
(IQR): [-58, 6 %], p = 0.02) in measured SI after the
OFF/ON dialysis transition, and a median increase of
?9 % (IQR -15 to 28 %, p = 0.7) after the ON/OFF
transition. Almost 90 % of patients exhibited decreased SI
at the OFF/ON transition, and 55 % exhibited increased SI
at the ON/OFF transition. Results indicate that HD com-
mencement has a significant effect on insulin pharmaco-
kinetics at a cohort and per-patient level. These changes in
metabolic behaviour are most likely caused by changes in
insulin clearance or/and endogenous insulin secretion.
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1 Introduction
Acute kidney injury (AKI) is a common complication
among critically ill patients, especially for elderly patients
with diabetes [1]. Approximately 36 % of critically ill
patients are diagnosed with AKI [1–3] with a significant
proportion progressing to severe AKI (Stage 3) [2],
requiring weekly haemodialysis (HD) [4]. Several epide-
miological studies have shown an increase in morbidity
and mortality following the development of severe AKI
[3, 5–7].
The increasing incidence of critically ill patients with
severe AKI may be explained by several factors, including
a rising incidence of sepsis [3, 4], major surgery (especially
cardiothoracic), nephrotoxic medications, and chronic
medical conditions [5]. With both uraemia and HD treat-
ment, glycaemic control (GC) can be complicated [6] as
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GC affects insulin secretion, insulin clearance, gluconeo-
genesis [7], and peripheral tissue sensitivity of insulin [8].
Many studies have claimed that HD treatment is necessary
to treat severe AKI patients by removing waste and toxins
[9]. Other clinical studies have shown that HD treatment
cleared plasma insulin through increased absorption [10–
12] through the dialyzer membrane, lowering insulin con-
centration. Also, abnormalities in insulin secretion have
important pathophysiological implications in the genesis of
AKI, which is responsible for the progressive reduction in
insulin requirement of diabetic patients who develop AKI
[13]. However, the effect of renal failure on insulin kinetics
in critically ill patients is still unclear due to the lack of
pharmacokinetic studies on insulin secretion and clearance
related to HD treatment. These unknown effects might
have the potential to complicate metabolic management
and the treatment itself.
In particular, insulin resistance is common in many
severe AKI patients [4, 14, 15]. Hence, these patients are at
risk of developing hyperglycaemia [6] with its associated
negative outcomes [16, 17]. The mechanism of glucose
intolerance in severe AKI patients is ambiguous [18].
DeFronzo et al. [21] and Mak [20] showed that insulin
resistance among severe AKI patients improved during a
10-week course of HD treatment. However, the net effect
of HD treatment on glycaemic regulation and insulin sen-
sitivity (SI) in a critically ill cohort is unknown.
This study uses dense clinical data and a model-based
analysis to investigate changes in a clinically validated
model-based SI metric at HD transitions in a cohort of
critically ill patients. It was hypothesized that the
observed SI would decrease during HD due to enhanced
insulin clearance compared to the model and would be
recaptured again when HD is stopped. These changes in
model-based SI would thus offer a unique observation of
insulin kinetics and action in this population of critically
ill patients with severe AKI that would better inform
metabolic care.
2 Materials and Methods
2.1 Patient Cohort
Retrospective blood glucose (G) measurements, nutrition
administration rates (P), and insulin delivery (UX) data
used in this study were obtained from the Specialized
Relative Insulin Nutrition Titration (SPRINT) pilot study
of 371 critically ill patients who required GC [21]. 51 of
the 371 patients had severe AKI treated with HD. The
exogenous insulin and nutrition given to these patients
were optimized to maximise blood glucose time in the
range of 4.0–7.0 mmol L-1, minimising hyperglycaemia,
via patient-specific nutrition and insulin administration
[12].
The 51 severe AKI patients were treated with HD with a
polysulfone (PS) dialyzer membrane (APS-15SA: Asahi
Medical Co., Ltd, Tokyo). This PS dialyzer membrane has
been reported to affect plasma insulin clearance during HD
treatment [22, 23]. Patients were subjected to HD three
times weekly (in a fasting state) for a minimum of 4 h in
the Christchurch Hospital Intensive Care Unit (ICU).
Study inclusion from 51 severe AKI patients required a
minimum of 5 h of patient data before dialysis, followed by
at least 6 h of dialysis, and then at least 5 h after dialysis.
The clinical details of this cohort are summarized in
Table 1. The APACHE III diagnosis for these patients can
be divided into 5 main groups: Sepsis, Cardiovascular,
Trauma, Respiratory, and Diabetes. Full details on SPRINT
can be obtained elsewhere [21].
2.2 Limitation of Study
The study is mainly focused on the (intermittent) HD
treatment as one of many treatments in managing severe
AKI. Continuous renal replacement therapy (life-support-
ing treatments) is commonly instituted in critical care when






All of these treatments are regarded as life-extending
treatments to support renal function. With dense clinical
data obtained from the SPRINT glycaemic protocol [21], it
is suggested for most critically ill patients to be treated
with HD in order to avoid other metabolic complications
Table 1 SPRINT cohort baseline variables (N = 51)
Median [IQR]
Age (years) 65 46–73
% male 76 %
APACHE II score 24 19–30






a Patients diagnosed with type 1 diabetes mellitus (T1DM)
Data are expressed as median values [IQR] (APACHE = Acute
Physiology And Chronic Health Evaluation)
126 U. K. Jamaludin et al.
123
such as sepsis and trauma [15]. Furthermore, the effects of
continuous renal replacement inter-therapies (as mentioned
above) can be discovered with a larger cohort with dif-
ferent AKI by observing the changes in insulin sensitivity
that affects insulin kinetics.
2.3 Identification of Model-Based SI
Model-based SI was identified hourly by fitting G mea-
surements with estimated endogenous insulin secretion
using the ICING (Intensive Control Insulin-Nutrition-
Glucose) model [24] with modification. An integral-based
method [25] and clinical data were used to identify a
patient-specific stepwise SI profile with a 1 h resolution.
The model nomenclatures are given in Table 2. It is
mathematically defined as:
G
 ðtÞ ¼ pGGðtÞ  SIGðtÞ QðtÞ
1 þ aGQðtÞ





ðtÞ ¼ nIðIðtÞ  QðtÞÞ  nC QðtÞ
1 þ aGQðtÞ ð2Þ
I
ðtÞ ¼ nKIðtÞ  nL IðtÞ
1 þ aI IðtÞ  nIðIðtÞ  QðtÞÞ þ
uex
VI
þ ð1  xLÞ uenðGÞ
VI
ð3Þ
P1 tð Þ ¼ d1P1 þ D tð Þ ð4Þ
P2 tð Þ ¼ min d2P2; Pmaxð Þ þ d1P1 ð5Þ
P tð Þ ¼ min d2P2; Pmaxð Þ þ PN tð Þ ð6Þ
uenðGÞ ¼
umin; umin [ k1GðtÞ þ k2
k1GðtÞ þ k2; umin  k1GðtÞ þ k2  umax





Model estimation of endogenous insulin secretion
(uen(G)) is in the range of 16.7–266.7 mU min
-1 as a
function of glycaemic level (G) [26]. This overall meta-
bolic model has been clinically validated with a median
prediction error of less than 5 % [27]. The model has been
used in several clinical GC trials and insulin sensitivity
tests [28, 29].
2.4 Hypothesis
Specifically, constant nK is used in model ICING describes
in Eqs. (1)–(6). While, uen model in Eq. (7) is dependent
on G values. Therefore, the unmodeled changes due to HD
or any other effect [30] are reflected in the model-based SI.
Two dialysis transitions, OFF/ON and ON/OFF, are
examined in this study.
2.4.1 OFF/ON Transition
The HD PS membrane is known to absorb plasma insulin
during dialysis treatment [23]. Therefore, it was hypothe-
sized that after the OFF/ON transition, SI will decrease
given a model assumption of a fixed uen which dependent
on G and a constant nK.
2.4.2 ON/OFF Transition
By using the same dialyzer membrane with the assump-
tions of a fixed uen (dependable on G) and a constant nK, it
was hypothesized that SI will increase as the plasma insulin
level recovers to higher levels after HD treatment ends.
Thus, changes in SI due to HD might be caused either
by:
(a) changes in uen due to HD treatment [14, 23]
(b) changes in the effective insulin clearance (nK in the
model) [31, 32]
However, only changes and the net effect of SI after both
transitions were tracked so the separate effects could not be
delineated. In particular, a rising of uen that is based on the
assumption of a fixed uen (dependable on G) leads to an
increase in the observed SI, while rising nK leads to an
apparent reduction in SI. If SI is decreasing, it means that
the effect of insulin clearance increases outweighs the
effect of uen increases.
2.5 Calculations and Statistical Analysis
Numerical calculations and parameter identification were
performed using MATLAB (The MathWorks Inc., Natick,





Blood glucose changes, DG, were calculated in a man-
ner similar to that for DSI to assess any changes in glyca-
emia that could affect results.
This analysis uses a 2 h moving average to reduce the
effect of measurement error and the influence of transient
effects. SI profiles are identified over periods starting at 3 h
before dialysis commencement until 4 h after dialysis ends.
This range ensures full settling of patient responses after
transitions. The patients’ blood glucose and insulin sensitivity
at both OFF/ON and ON/OFF dialysis transitions are illus-
trated on distribution and Bland–Altman plots.
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Non-parametric Wilcoxon rank sum tests were used to
assess DSI and DG over the cohort at each transition.
3 Results
Figures 1 and 2 show Bland–Altman plots of DG and DSI
over the OFF/ON and ON/OFF dialysis transitions. DG and
DSI at the ON/OFF transition are unbiased overall, but SI is
biased (median DSI = -29 %, p = 0.02) over the OFF/
ON dialysis transition (Fig. 1b).
At the OFF/ON dialysis transition, the G distribution is
effectively maintained within 4–7 mmol L-1 except for
two patients with sepsis and cardiovascular diagnoses.
Figure 3 shows DSI over 6 h at the OFF/ON and ON/
OFF dialysis transitions. Patients diagnosed with pancrea-
titis, diabetes, and other metabolic dysfunctions showed
larger variance in DSI ([-150 %). However, the trend at
Table 2 Nomenclature of ICING-2 Model
Parameters Description Unit
G Blood glucose level mmol L-1
Q Interstitial insulin level mU L-1
I Plasma insulin level mU L-1
P1 Stomach glucose content mmol
P2 Gut glucose content mmol
P Rate of glucose appearance in plasma mmol min-1
uen Endogenous insulin secretion rate mU min
-1
Parameters and kinetic values of ICING-2 model based on diabetic status
EGP Endogenous glucose production rate 1.16 mmol min-1
CNS Central nervous system glucose uptake 0.3 mmol min-1
pG Patient endogenous glucose removal 0.006 min
-1
SI Insulin sensitivity L mU
-1 min-1
aG Saturation parameter of insulin-mediated glucose removal 0.0154 L mU
-1
VG Plasma glucose distribution volume 13.3 L
nI Plasma-interstitium insulin diffusion rate 0.006 min
-1
nC Receptor-bound insulin degradation 0.006 min
-1
nK Renal insulin clearance 0.0542 min
-1
nL Hepatic insulin clearance 0.1578 min
-1
aI Saturation parameter for hepatic insulin clearance 0.0017 L mU
-1
VI Insulin distribution volume 4.0 L
xL First pass hepatic clearance 0.67




Pmax Maximal gut glucose flux 6.11 mmol min
-1
umax Maximum pancreatic secretion rate 266.7 mU min
-1
umin Minimum pancreatic secretion rate 16.7 mU min
-1




k2 Pancreatic insulin secretion offset *NGT -49.9 mUmin-1
*T2DM -27.4
*T1DM 16.7
Exogenous input variables of ICING-2 model
uex Intravenous insulin input rate mU min
-1
D Oral glucose input rate from enteral nutrition mmol min-1
PN Intravenous glucose input rate from parenteral nutrition mmol min-1
* NGT = normal glucose tolerance, T1DM = type 1 diabetes mellitus, T2DM = type 2 diabetes mellitus
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the OFF/ON transition in Fig. 3a (and Fig. 1) is much
clearer.
Table 3 summarises DSI over the OFF/ON and ON/OFF
transitions. SI decreased after the OFF/ON dialysis transi-
tion until t = 2 h, where it settled with median DSI =
-29 % (interquartile range (IQR): [-58,6] %, p = 0.02).
There were a comparatively low number of confounders,
indicating a relatively strong effect. Median DSI increased
by 9 % for the ON/OFF transition (Table 3), (IQR:
[-15,28] %; p = 0.7) at t = 3 h after the ON/OFF tran-
sition. The number of confounders is significantly higher
for the ON/OFF transition and the p values indicate that the
hypothesized effect cannot be confirmed at this transition.
G remains effectively constant at both transitions (Figs. 1,
2). However, changes in SI outcomes were not significant
(p [ 0.05) even 4 h after the ON/OFF transition.
An extended dialysis interval ([10 h) of DSI for both
OFF/ON and ON/OFF dialysis transitions across the
N = 26 subjects with sufficient data is shown in Table 4. SI
decreased during the OFF/ON dialysis interval until
t = 8 h, where it settled to a median reduction of -25 %
(IQR: [-10, -51] %; p = 0.04). There were only 2 con-
founders (DSI [ 0) from the 26 patients at t = 8 h. How-
ever, while the ON/OFF transition results improved
relative to the hypothesized effect, the results were still
insignificant (p [ 0.07).
4 Discussion
This study investigated the effect of dialysis on renal
insulin clearance, endogenous insulin secretion, and
Fig. 1 Bland–Altman plots of a DG and b DSI over the OFF/ON dialysis transition between t = -1 and 2 for severe AKI patients (N = 51).
Median DG = 8 % and median DSI = -29 %
Fig. 2 Bland–Altman plots of
a DG and b DSI over the ON/
OFF dialysis transition between
t = -1 and 2 for severe AKI
patients (N = 51). Median
DG = -8 % and median
DSI = 10 %
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effective plasma insulin through a clinically validated
model-based DSI metric at both OFF/ON and ON/OFF
dialysis transitions. Significant insulin sensitivity changes
were observed at the OFF/ON dialysis transition
(p = 0.02). This analysis indicates that model-based SI
decreased over the initial 4 h after HD started and that the
changes occurred as rapidly as 2 h. This result implies that
dialysis significantly affects plasma insulin levels via
changes in renal insulin clearance and/or endogenous
insulin secretion, compared to baseline model assumptions.
Glucose intolerance among critically ill patients with
severe AKI occurs with significant inhibition of insulin
secretion and a state of peripheral insulin resistance [14,
33] on top of insulin resistance from the critical illness
[34]. It has also been reported that in patients with severe
AKI, insulin resistance occurred even though glomerular
filtration rate (GFR) values were still within the normal
range [35]. The effect of insulin resistance can be exacer-
bated by impairment of the role of insulin in maintaining
the hepatic glucose balance [19]. Specifically, an inability
of insulin to stimulate hepatic glucose uptake with
decreasing SI has been observed in severe AKI patients
[36]. Thus, understanding the pharmacokinetics of insulin
during dialysis is clinically important.
Plasma insulin is reduced by enhanced insulin clearance
due to the PS dialyzer membrane [22, 23] used during HD
treatment in this study. It is suggested that the most sig-
nificant reduction in plasma insulin during HD treatment is
through absorption of insulin across the PS membrane [23],
where the equilibrium amount of insulin absorbed was
greatest in positively charged membranes [31]. A signifi-
cant uptake and degradation of insulin may occur when
renal insulin clearance significantly exceeds the glomerular
filtration rate [6], as would occur in HD treatment. This
enhanced insulin clearance rate and accumulation of dia-
lyzable uraemic toxins can cause inhibition of insulin
degradation and can be sufficiently normalized by HD
treatment [20].
Plasma insulin levels also depend on endogenous insulin
secretion. Physiologically, uen is determined by the
Fig. 3 Patient distribution for
dialysis period of 6 h at OFF/
ON (a) and ON/OFF (b) dialysis
transitions from t = -2 to
t = 4 h
Table 3 Results for OFF/ON and ON/OFF dialysis transitions of 6 h with inverted SI confounders (t = -2 to t = 4, N = 51)
Time t (hr) OFF/ON (N = 51), expect DSI \ 0 ON/OFF (N = 51), expect DSI [ 0
QI (%) Q2 (%) Q3 (%) p value DSI [ 0 %
(confounders)
Q1 (%) Q2 (%) Q3 (%) p value DSI \ 0 %
(confounders)
-2 -7 1 10 0.9 31 61 -13 -4 3 0.7 32 63
-1 0 0 0 1 0 0 0 0 0 1 0 0
0 -24 -7 -1 0.3 10 20 -5 1 8 0.9 24 47
1 -45 -14 -2 0.05 7 14 -7 2 15 0.9 23 45
2 -58 -29 -6 0.02 5 10 -13 4 26 0.8 21 41
3 -55 -19 -5 0.03 9 18 -15 9 28 0.7 23 45
4 -46 -22 -5 0.03 6 12 -15 3 31 0.5 24 47
The results show DSI quartiles and number of confounders with DSI in direction opposite to median trend hypothesized. Q2 = median = 50 %
percentiles result. * p values measured using Wilcoxon rank sum tests, Q1 = 25 % percentile, Q3 = 75 % percentile
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glycaemic level and the ability of b cells to respond to
blood glucose level and its changes. However, it was
suggested that an increase in endogenous insulin secretion
may occur in response to HD treatment with a PS mem-
brane dialyzer due to reductions in plasma insulin [10, 22].
In particular, a PS membrane can reduce plasma insulin
significantly in HD [10, 23]. Thus, SI is also expected to
decrease with an unmodeled increase in uen during the
initial period of HD treatment to maintain the G level.
The model-based DSI at the ON/OFF dialysis transition
in this study was insignificant (p [ 0.05). It is assumed that
acute intravenous (i.v.) administration of 1,25-di-
hydroxyvitamin D3 (1,25(OH)2D3) given to severe AKI
patients during HD may increase insulin secretion and
reverse glucose intolerance [20]. An improvement in glu-
cose metabolism has been observed in some studies via
lower mean glucose during dialysis and a more rapid dis-
appearance rate of glucose in the immediate post-dialysis
period [37]. In general, glucose metabolism and renal
function are expected to increase gradually after post-
dialysis when toxic substances that are suspected of hin-
dering renal function have been extracted. Long-term
(4.9 weeks) HD treatment has been shown to normalize
insulin sensitivity and result in a marked improvement in
glucose metabolism [11], but this might not completely
normalize glucose utilization [19]. Overall, it is impossible
to delineate the effects that contribute to changes in SI in
this study, due to model identifiability issues [16] and the
side effects of other diagnosed critical illnesses apart from
severe AKI [18]. Over longer intervals, as in Table 4, inter-
patient or intra-patient variation may further obscure the
observation of the effect itself [28].
Thus, a substantial change in SI at the OFF/ON dialysis
transition indicates a strong and fast process of the
cleaning and clearing of toxic substances from blood,
improving effective SI due to either decreased uen or
increased nK clearance. However, at the ON/OFF dialysis
transition, the recovery process to regulate and normalize
blood is a lot slower physiologically. Hence, the model-
based SI after dialysis may be expected to remain
unchanged, as observed here, even for extended periods
after HD treatment.
The model-based SI is an indication of overall glucose
metabolism of critically ill patients and does not neces-
sarily reflect the precise cellular physiology of peripheral
insulin sensitivity. The model-based DSI at a cohort level
used in this study are unlikely to be caused by actual
variance in true peripheral SI at a cellular level. In partic-
ular, there is no apparent stimulus induced by HD to
directly affect SI. Thus, DSI reflects changes in renal
clearance or/and endogenous insulin secretion, which in
turn result in changes in the model-based SI calculated
based on fixed assumptions for these values.
In particular, the ICING model prediction of uen is made
in terms of blood glucose level in the absence of direct
measurement of C-peptide. Hence, the effect of dialysis on
uen cannot be defined patient-specifically by the model
without added data that was not available in this study.
Alternatively, it has been reported that endogenous insulin
secretion is also affected by exogenous insulin [38]. As
Table 4 Extended results for OFF/ON and ON/OFF dialysis transitions of [10 h with inverted SI confounders (t = -2 to t = 10, N = 26)
Time t (hr) OFF/ON (N = 26), expect DSI \ 0 ON/OFF (N = 26), expect DSI [ 0
QI (%) Q2 (%) Q3 (%) p value DSI [ 0 %
(confounders)
Q1 (%) Q2 (%) Q3 (%) p value DSI \ 0 %
(confounders)
-2 -4 3 13 0.9 16 62 -15 -6 1 0.7 19 73
-1 0 0 0 1 0 0 0 0 0 1 0 0
0 -25 -10 -2 0.4 4 15 -5 3 9 0.8 10 28
1 -44 -23 -4 0.1 3 12 -7 8 17 0.8 11 42
2 -56 -30 -6 0.09 2 8 -8 13 32 0.6 9 35
3 -55 -19 -2 0.09 6 23 -4 18 42 0.3 9 35
4 -53 -24 -4 0.1 4 15 -13 14 36 0.3 10 28
5 -53 -29 -8 0.08 4 15 -12 22 44 0.2 10 28
6 -44 -25 -8 0.1 4 15 -6 23 47 0.1 8 31
7 -40 -21 -9 0.07 3 12 -5 18 50 0.07 7 27
8 -51 -25 -10 0.04 2 8 -5 19 39 0.07 7 27
9 -47 -18 -7 0.04 1 4 -6 22 38 0.07 8 31
10 -45 -12 -3 0.09 5 19 -4 22 41 0.08 8 31
The results show DSI quartiles and number of confounders with DSI in direction opposite to median trend hypothesized. Q2 = median = 50 %
percentile result. * p values measured using Wilcoxon rank sum tests, Q1 = 25 % percentile, Q3 = 75 % percentile
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plasma insulin levels are suspected to decrease during
dialysis, it is suspected that endogenous insulin secretion
would increase at a cohort level. Thus, an increase in the
model-based SI over time should be observed at the OFF/
ON transition, contrary to the observations here. Hence, uen
dependence on blood glucose level would confound the
observed effect and can be discounted as a contributor to
the shifts in the model-based SI in this study. Thus, it is
most likely that effective renal clearance increases during
HD and decreases after HD treatment.
Effective uen identification cannot be undertaken with
only glucose data [16, 39]. Thus, a direct measurement of
C-peptide should be included for direct quantification of
the effects contributing to the glycaemia of severe AKI
patients. The results of this study could be used to confirm
these results in order to power a further study that segre-
gates these potential contributing effects.
All critically ill patients with severe AKI in this study
were undergoing SPRINT tight glycaemic control (TGC),
where the minimal changes in G illustrated that SPRINT
was successful in controlling glycaemia during these
transitions. A consistent trend of DG below the 5th per-
centile was observed for patients with cardiovascular,
respiratory, and trauma compared to the patient diagnosed
with sepsis, as shown in Fig. 1a. It portrays sepsis com-
plications due to severe infections and multiple organ
dysfunctions [40], which were not the main focus in this
study. Thus, glycaemic levels and the tightness of this
protocol are used to ensure that the analysis results are not
biased by variations in glucose levels which can affect
stress response and thus SI levels. SPRINT clinical results
were also compared with the simulation results to validate
and minimize the prediction errors of the protocol.
Although there were two diagnosed diabetics, almost no
bias in DG was observed. Thus, the confounding factor
plays no role.
Overall, this investigation suggests that the most likely
contributor to the observed changes in SI was the HD
insulin clearance, which was modeled by the renal insulin
clearance term. The effect of HD on plasma insulin and the
mechanism of insulin clearance among critically ill patients
with severe AKI were shown in this study to be a con-
tributor to overall effective SI, which determines the gly-
caemic level, all else being equal. However, further in-
depth studies must be undertaken to measure the specific
effects of HD in different AKI stages. A prospective cohort
and clinical studies with direct insulin and C-peptide assays
on this cohort may lead to a better understanding of insulin
kinetics during HD treatment. A broad comparison from a
different cohort of varied HD duration with mixed levels of
insulin will also clarify the effects of DSI, revealing further
details in the underlying contributors of specific insulin
resistance.
5 Conclusion
The distinct change in model-based insulin sensitivity
during HD treatment was a significant and observable
aspect of critically ill patient physiology. The findings were
consistent with the presence of effects of HD treatment in a
majority of severe AKI patients from other studies. Clini-
cally, the effect of the main contributors (nK and uen) to
effective insulin sensitivity changes during HD from a
baseline model or clinical assumptions suitable for other
patients should also be considered in GC. However, the
precise pharmaco-kinetics/dynamics driving this change
remain ambiguous. These results justify a larger cohort
investigation with specific measurement of insulin secre-
tion and renal clearance to differentiate these impacts.
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